Singapore markets closed

Precision BioSciences, Inc. (DTIL)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.4018-0.0032 (-0.79%)
As of 12:38PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.4050
Open0.4045
Bid0.3996 x 1000
Ask0.4001 x 1100
Day's range0.3951 - 0.4098
52-week range0.2750 - 1.4500
Volume245,748
Avg. volume878,804
Market cap48.987M
Beta (5Y monthly)1.40
PE ratio (TTM)N/A
EPS (TTM)-0.8600
Earnings date07 Mar 2024 - 11 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.63
  • Business Wire

    Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases

    DURHAM, N.C., December 04, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced publication in the journal Nature Metabolism of a peer reviewed manuscript titled "Efficient elimination of MELAS-associated m.3243G mutant mitochondrial DNA by an engineered mitoARCUS nuclease." This

  • Business Wire

    Precision BioSciences to Present at Hep-DART 2023

    DURHAM, N.C., November 30, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the company will present at Hep-DART 2023 in an industry session and host a poster presentation on December 5, 2023, in Los Cabos, Mexico.

  • Business Wire

    Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

    DURHAM, N.C., November 28, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on November 21, 2023, the Compensation Committee of Precision’s Board of Directors approved the grant of an inducement award to a new employee under the Precision BioSciences, Inc. 2021 Employmen